| 中文名称 | 匹莫苯丹 |
|---|---|
| 中文别名 | 匹莫苯;匹莫苯丹;4-(4-三氟甲基嘧啶-2-基)哌嗪-1-甲酸叔丁酯;6-[2-(4-甲氧基苯基)-1H-苯并咪唑-5-基]-5-甲基-4,5-二氢-3(2H)-哒嗪酮;匹莫苯 标准品;匹莫苯,匹莫苯丹;匹莫苯丹 EP标准品;匹莫苯丹系统适用性 EP标准品;4,5-二氢-5-甲基-6-[2-(4-甲氧基苯基)-1H-苯并咪唑-5-基]-3(2H)一哒嗪酮 |
| 英文名称 | Pimobendan |
| 英文别名 | Pimobendan;rac Pimobendan;3(2H)-Pyridazinone, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-;4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone;Pimobendam;pimobendane;(RS)-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-4,5-dihydropyridazin-3(2H)-one;2-(4-methoxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6-pyridazinyl) benzimidazole;Acardi;dl-Pimobendan;Pimobendanum;UD-CG 115;UD-CG115 BS;VetMedin;4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-3(2H)-pyridazinone;d-Pimobendan;l-Pimobendan;Racemic pinobendan;(+)-Pimobendan;(-)-Pimobendan;Pimobendan (Vetmedin);Pimobendanum [INN-Latin];Pimobendane [INN-French];Pimobendan [INN-Spanish];9HTU209Z0N;613JXV89SU;AK482253;4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyri;(+/-)-4,5-DIHYDRO-6-(2-(P-METHOXYPHENYL)-5-BENZIMIDAZOLYL)-5-METHYL-3(2H)-PYRIDAZINONE;(-)-4,5-Dihydro-6-(2-(4-methoxyphenyl)-1H-benzimidazol-5-yl)-5-methyl-3(2H)-pyridazinone;DTXCID9028255;AC-689;UD-CG115;BCP0726000255;KUC109647N;SMR002530068;BDBM50282617;(-)-UD-CG 115BS;Q414351;6-(2-(4-Methoxyphenyl)-4,5-dihydro-1H-benzimidazol-5-yl)-5-methyl-3(2H)-pyridazinone;FORTEKOR PLUS COMPONENT PIMOBENDAN;UD-CG 115 BS;Pimobendan,USP;6-(2-(4-methoxyphenyl)-1H-benzo[d]imidazol-6-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one;PIMOBENDAN (USP-RS);SolutitionKitsPimobendan;74150-27-9;KSC-210-009;SCHEMBL27623;Pimobendan (INN-Spanish);3(2H)-Pyridazinone, 4,5-dihydro-6-(2-(4-methoxyphenyl)-1H-benzimidazol-5-yl)-5-methyl-;118428-37-8;NCGC00274063-01;UNII-613JXV89SU;PIMOBENDAN (MART.);CHEMBL24646;4,5-dihydro-6-[2-(4-methoxy-phenyl)-1h-benzimidazol-5-yl]-5-methyl-3 (2h)-pyridazinone;MLS006010188;Pimobendan EP5;EN300-27067685;Pimobendan for system suitability, European Pharmacopoeia (EP) Reference Standard;Vetmedin-CA1;PIMOBENDAN [USAN];PIMOBENDAN [USP-RS];HMS3884C21;FT-0630830;3(2H)-PYRIDAZINONE, 4,5-DIHYDRO-6-(2-(4-METHOXYPHENYL)-1H-BENZIMIDAZOL-5-YL)-5-METHYL-, (+/-)-;Pimobendan [USAN:INN:BAN];UNII-34AP3BBP9T;4,5-dihydro-6-(2-(4-methoxyphenyl)-1H-benzimidazole-5-yl)-5-methyl-3(2H)-pyridazinone;PIMOBENDAN (EP IMPURITY);PIMOBENDAN [MI];SW219717-1;CCG-267853;AB01274800-01;3(2H)-Pyridazinone, 4,5-dihydro-6-(2-(4-methoxyphenyl)-1H-benzimidazol-5-yl)-5-methyl-, (-)-;VetmedinChew;118428-36-7;Pimobendan (JAN/USAN/INN);UNII-9HTU209Z0N;NCGC00274063-05;PIMOBENDAN [GREEN BOOK];PIMOBENDAN COMPONENT OF FORTEKOR PLUS;AKOS015967705;Pimobendane (INN-French);PIMOBENDAN (USP MONOGRAPH);3(2H)-PYRIDAZINONE, 4,5-DIHYDRO-6-(2-(4-METHOXYPHENYL)-1H-BENZIMIDAZOL-6-YL)-5-METHYL-;(+)-UD-CG 115BS;Pimobendan, >=98% (HPLC);DTXSID8048280;PIMOBENDAN [INN];Racemic pimobendan;Pimobendan, United States Pharmacopeia (USP) Reference Standard;PIMOBENDAN [USP MONOGRAPH];PIMOBENDAN (EMA EPAR VETERINARY);P2779;D01133;PIMOBENDAN [EP IMPURITY];AKOS015851937;Pimobendan 100 microg/mL in... |
| CAS No. | 74150-27-9 |
| 分子式 | C19H18N4O2 |
| 分子量 | 334.37 |
4-(2-((2R,3R)-3-(2,5-二氟苯基)-3-羟基-4-(1H-1,2,4-三唑-1-基)丁-2-基)噻唑-4-基)苯甲腈
N-(丁基磺酰基)-O-[4-(4-哌啶基)丁基]-L-酪氨酸盐酸盐一水合物
2-(4-(1-羟基-4-(4-(羟基二苯基甲基)哌啶-1-基)丁基)苯基)-2-甲基丙酸
7-环戊基-N,N-二甲基-2-((5-(哌嗪-1-基)吡啶-2-基)氨基)-7H-吡咯并[2,3-d]嘧啶-6-甲酰胺
(1-((2R,3R,4S,5R)-3,4-二羟基-5-甲基四氢呋喃-2-基)-5-氟-2-氧代-1,2-二氢嘧啶-4-基)氨基甲酸戊酯
((3S,5R)-5-((1H-1,2,4-三唑-1-基)甲基)-5-(2,4-二氟苯基)四氢呋喃-3-基)甲基 4-甲基苯磺酸酯
N-(3-氯-4-氟苯基)-7-甲氧基-6-(3-吗啉-4-丙氧基)喹唑啉-4-胺
(6R,7R)-3-甲基-7-[(R)-2-氨基-2-苯乙酰氨基]-8-氧-5-硫杂-1-双环[4.2.0]辛-2-烯-2-甲酸
(2R,3S,5S)-3-苄氧基-5-[2-[[(4-甲氧基苯基)二苯基甲基]氨基]-6-苄氧基-9H-嘌呤-9-基]-2-苄氧基甲基环戊醇
(2R,3R,4S,5R)-2-(4-氨基吡咯并[2,1-F][1,2,4]三嗪-7-基)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-甲腈
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。
CopyRight @2025 广东元丰化学试剂有限公司 版权所有 | 隐私政策 条款及条件 | 粤ICP备2025403430号-1
技术支持:库价化学